Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Polycystic Ovary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Breast Neoplasms 3Neoplasms 2Fatigue 2Weight Loss 1Systemic carnitine deficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurotoxicity Syndromes 1Muscular Atrophy 1Muscle Weakness 1Motor Activity 1Malnutrition 1Leukemia, Biphenotypic, Acute 1Insulin Resistance 1Hyperbilirubinemia 1Hyperandrogenism 1Hirsutism 1Heart Failure 1Gastrointestinal Stromal Tumors 1Dyslipidemias 1Depression 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Cachexia 1Burkitt Lymphoma 1Basal Cell Nevus Syndrome 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 3Nutrition Assessment 3Exercise 3Carvedilol 3dapagliflozin 2Standard of Care 2Rituximab 2Ivabradine 2Control Groups 2Atorvastatin 2pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Vincristine 1Valsartan 1Trastuzumab 1Surveys and Questionnaires 1Spironolactone 1Sodium Chloride 1Simendan 1Secondary Prevention 1Resistance Training 1Pyruvic Acid 1Prednisolone 1Practice Guidelines as Topic 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Heart Failure × Carnitine × Clear all
NCT00247975 2022-08-16

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Ottawa Heart Institute Research Corporation

Phase 2/3 Terminated
36 enrolled
Breast

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡